| Dr Frances Ortiz, PHARMD, MBA, CPH | |
|
22 Calle Barbosa, Adjuntas, PR 00601-2209 | |
| (787) 829-3305 | |
| (787) 836-7243 |
| Full Name | Dr Frances Ortiz |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 22 Calle Barbosa, Adjuntas, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659456127 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 4961 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frances Ortiz, PHARMD, MBA, CPH Po Box 963, Adjuntas, PR 00601-0963 Ph: (787) 677-9324 | Dr Frances Ortiz, PHARMD, MBA, CPH 22 Calle Barbosa, Adjuntas, PR 00601-2209 Ph: (787) 829-3305 |
News Archive
The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.
A routine blood test that measures kidney function can be a valuable predictor of short-term outcomes for stroke patients, according to a study led by a neurologist at Wake Forest Baptist Medical Center.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and arterial disease, today reported that it has initiated an open-label, multicenter Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E."
An international research group, including scientists at the University of Maryland School of Medicine, studying 520,000 people from around the world has identified 22 new genetic risk factors for stroke, tripling the number of gene regions known to affect stroke risk.
› Verified 3 days ago
Mrs. Nelida Velez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 36 Bartolomei, Urb. San Joaquin, Adjuntas, PR 00601 Phone: 787-829-2907 | |
Mrs. Jenilsa Velez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 21 Calle San Joaquin, Adjuntas, PR 00601 Phone: 787-829-2480 Fax: 787-829-6000 | |
Ivette Ramos Gonzalez, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Munoz Rivera, #26, Adjuntas, PR 00601 Phone: 787-829-2495 Fax: 787-829-2495 | |
Anibal Rodriguez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22 Calle Barbosa, Adjuntas, PR 00601 Phone: 787-829-3305 Fax: 787-829-7187 | |
Mrs. Nivia Mercado, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22 Calle Barbosa, Adjuntas, PR 00601 Phone: 787-829-3305 Fax: 787-829-7187 | |
Karen Lyzette Piazza, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 21 Calle San Joaquin, Adjuntas, PR 00601 Phone: 787-829-2480 |